Evidence map›Paper›PMID 28416568›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2017

Pharmacological and Toxicological Properties of the Potent Oral

Steven L Wagner, Kevin D Rynearson, Steven K Duddy, Can Zhang, Phuong D Nguyen, Ann Becker, Uyen Vo, Deborah Masliah, Louise Monte, Justin B Klee and 9 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 45 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Air pollution amyloidogenesis is attenuated by the gamma-secretase modulator GSM-15606.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
  8. Article
  9. The Intricate Notch Signaling Dynamics in Therapeutic Realms of Cancer.ACS pharmacology & translational science · 2023
    Review
  10. Endotype reversal as a novel strategy for screening drugs targeting familial Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022
    Article
  11. Article
  12. Review
  13. Article
  14. Targeting Notch in oncology: the path forward.Nature reviews. Drug discovery · 2021
    Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 2 institutions in 1 country.

Steven L WagnerDepartment of Neurosciences, University of California, San Diego, La Jolla, California (S.L.W., K.D.R., P.D.N., A.B., U.V., D.M., L.M., W.C.M., R.A.R.); Integrated Nonclinical Development Solutions, Ann Arbor, Michigan (S.K.D.); NuPharmAdvise, Sanbornton, New Hampshire (G.J.); Biopharm Consulting Partners, Ambler, Pennsylvania (J.H.L.); and Genetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, Massachusetts (C.Z., J.B.K., C.M.E., W.X., L.Q., D.Y.K., R.E.T.) slwagner@ucsd.edu.
Kevin D RynearsonDepartment of Neurosciences, University of California, San Diego, La Jolla, California (S.L.W., K.D.R., P.D.N., A.B., U.V., D.M., L.M., W.C.M., R.A.R.); Integrated Nonclinical Development Solutions, Ann Arbor, Michigan (S.K.D.); NuPharmAdvise, Sanbornton, New Hampshire (G.J.); Biopharm Consulting Partners, Ambler, Pennsylvania (J.H.L.); and Genetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, Massachusetts (C.Z., J.B.K., C.M.E., W.X., L.Q., D.Y.K., R.E.T.).
Steven K DuddyDepartment of Neurosciences, University of California, San Diego, La Jolla, California (S.L.W., K.D.R., P.D.N., A.B., U.V., D.M., L.M., W.C.M., R.A.R.); Integrated Nonclinical Development Solutions, Ann Arbor, Michigan (S.K.D.); NuPharmAdvise, Sanbornton, New Hampshire (G.J.); Biopharm Consulting Partners, Ambler, Pennsylvania (J.H.L.); and Genetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, Massachusetts (C.Z., J.B.K., C.M.E., W.X., L.Q., D.Y.K., R.E.T.).
Can ZhangDepartment of Neurosciences, University of California, San Diego, La Jolla, California (S.L.W., K.D.R., P.D.N., A.B., U.V., D.M., L.M., W.C.M., R.A.R.); Integrated Nonclinical Development Solutions, Ann Arbor, Michigan (S.K.D.); NuPharmAdvise, Sanbornton, New Hampshire (G.J.); Biopharm Consulting Partners, Ambler, Pennsylvania (J.H.L.); and Genetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, Massachusetts (C.Z., J.B.K., C.M.E., W.X., L.Q., D.Y.K., R.E.T.).
Phuong D NguyenDepartment of Neurosciences, University of California, San Diego, La Jolla, California (S.L.W., K.D.R., P.D.N., A.B., U.V., D.M., L.M., W.C.M., R.A.R.); Integrated Nonclinical Development Solutions, Ann Arbor, Michigan (S.K.D.); NuPharmAdvise, Sanbornton, New Hampshire (G.J.); Biopharm Consulting Partners, Ambler, Pennsylvania (J.H.L.); and Genetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, Massachusetts (C.Z., J.B.K., C.M.E., W.X., L.Q., D.Y.K., R.E.T.).
Ann BeckerDepartment of Neurosciences, University of California, San Diego, La Jolla, California (S.L.W., K.D.R., P.D.N., A.B., U.V., D.M., L.M., W.C.M., R.A.R.); Integrated Nonclinical Development Solutions, Ann Arbor, Michigan (S.K.D.); NuPharmAdvise, Sanbornton, New Hampshire (G.J.); Biopharm Consulting Partners, Ambler, Pennsylvania (J.H.L.); and Genetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, Massachusetts (C.Z., J.B.K., C.M.E., W.X., L.Q., D.Y.K., R.E.T.).
Uyen VoDepartment of Neurosciences, University of California, San Diego, La Jolla, California (S.L.W., K.D.R., P.D.N., A.B., U.V., D.M., L.M., W.C.M., R.A.R.); Integrated Nonclinical Development Solutions, Ann Arbor, Michigan (S.K.D.); NuPharmAdvise, Sanbornton, New Hampshire (G.J.); Biopharm Consulting Partners, Ambler, Pennsylvania (J.H.L.); and Genetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, Massachusetts (C.Z., J.B.K., C.M.E., W.X., L.Q., D.Y.K., R.E.T.).
Deborah MasliahDepartment of Neurosciences, University of California, San Diego, La Jolla, California (S.L.W., K.D.R., P.D.N., A.B., U.V., D.M., L.M., W.C.M., R.A.R.); Integrated Nonclinical Development Solutions, Ann Arbor, Michigan (S.K.D.); NuPharmAdvise, Sanbornton, New Hampshire (G.J.); Biopharm Consulting Partners, Ambler, Pennsylvania (J.H.L.); and Genetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, Massachusetts (C.Z., J.B.K., C.M.E., W.X., L.Q., D.Y.K., R.E.T.).
Louise MonteDepartment of Neurosciences, University of California, San Diego, La Jolla, California (S.L.W., K.D.R., P.D.N., A.B., U.V., D.M., L.M., W.C.M., R.A.R.); Integrated Nonclinical Development Solutions, Ann Arbor, Michigan (S.K.D.); NuPharmAdvise, Sanbornton, New Hampshire (G.J.); Biopharm Consulting Partners, Ambler, Pennsylvania (J.H.L.); and Genetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, Massachusetts (C.Z., J.B.K., C.M.E., W.X., L.Q., D.Y.K., R.E.T.).
Justin B KleeDepartment of Neurosciences, University of California, San Diego, La Jolla, California (S.L.W., K.D.R., P.D.N., A.B., U.V., D.M., L.M., W.C.M., R.A.R.); Integrated Nonclinical Development Solutions, Ann Arbor, Michigan (S.K.D.); NuPharmAdvise, Sanbornton, New Hampshire (G.J.); Biopharm Consulting Partners, Ambler, Pennsylvania (J.H.L.); and Genetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, Massachusetts (C.Z., J.B.K., C.M.E., W.X., L.Q., D.Y.K., R.E.T.).
Corinne M EchmalianDepartment of Neurosciences, University of California, San Diego, La Jolla, California (S.L.W., K.D.R., P.D.N., A.B., U.V., D.M., L.M., W.C.M., R.A.R.); Integrated Nonclinical Development Solutions, Ann Arbor, Michigan (S.K.D.); NuPharmAdvise, Sanbornton, New Hampshire (G.J.); Biopharm Consulting Partners, Ambler, Pennsylvania (J.H.L.); and Genetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, Massachusetts (C.Z., J.B.K., C.M.E., W.X., L.Q., D.Y.K., R.E.T.).
Weiming XiaDepartment of Neurosciences, University of California, San Diego, La Jolla, California (S.L.W., K.D.R., P.D.N., A.B., U.V., D.M., L.M., W.C.M., R.A.R.); Integrated Nonclinical Development Solutions, Ann Arbor, Michigan (S.K.D.); NuPharmAdvise, Sanbornton, New Hampshire (G.J.); Biopharm Consulting Partners, Ambler, Pennsylvania (J.H.L.); and Genetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, Massachusetts (C.Z., J.B.K., C.M.E., W.X., L.Q., D.Y.K., R.E.T.).
Luisa QuintiDepartment of Neurosciences, University of California, San Diego, La Jolla, California (S.L.W., K.D.R., P.D.N., A.B., U.V., D.M., L.M., W.C.M., R.A.R.); Integrated Nonclinical Development Solutions, Ann Arbor, Michigan (S.K.D.); NuPharmAdvise, Sanbornton, New Hampshire (G.J.); Biopharm Consulting Partners, Ambler, Pennsylvania (J.H.L.); and Genetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, Massachusetts (C.Z., J.B.K., C.M.E., W.X., L.Q., D.Y.K., R.E.T.).
Graham JohnsonDepartment of Neurosciences, University of California, San Diego, La Jolla, California (S.L.W., K.D.R., P.D.N., A.B., U.V., D.M., L.M., W.C.M., R.A.R.); Integrated Nonclinical Development Solutions, Ann Arbor, Michigan (S.K.D.); NuPharmAdvise, Sanbornton, New Hampshire (G.J.); Biopharm Consulting Partners, Ambler, Pennsylvania (J.H.L.); and Genetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, Massachusetts (C.Z., J.B.K., C.M.E., W.X., L.Q., D.Y.K., R.E.T.).
Jiunn H LinDepartment of Neurosciences, University of California, San Diego, La Jolla, California (S.L.W., K.D.R., P.D.N., A.B., U.V., D.M., L.M., W.C.M., R.A.R.); Integrated Nonclinical Development Solutions, Ann Arbor, Michigan (S.K.D.); NuPharmAdvise, Sanbornton, New Hampshire (G.J.); Biopharm Consulting Partners, Ambler, Pennsylvania (J.H.L.); and Genetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, Massachusetts (C.Z., J.B.K., C.M.E., W.X., L.Q., D.Y.K., R.E.T.).
Doo Y KimDepartment of Neurosciences, University of California, San Diego, La Jolla, California (S.L.W., K.D.R., P.D.N., A.B., U.V., D.M., L.M., W.C.M., R.A.R.); Integrated Nonclinical Development Solutions, Ann Arbor, Michigan (S.K.D.); NuPharmAdvise, Sanbornton, New Hampshire (G.J.); Biopharm Consulting Partners, Ambler, Pennsylvania (J.H.L.); and Genetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, Massachusetts (C.Z., J.B.K., C.M.E., W.X., L.Q., D.Y.K., R.E.T.).
William C MobleyDepartment of Neurosciences, University of California, San Diego, La Jolla, California (S.L.W., K.D.R., P.D.N., A.B., U.V., D.M., L.M., W.C.M., R.A.R.); Integrated Nonclinical Development Solutions, Ann Arbor, Michigan (S.K.D.); NuPharmAdvise, Sanbornton, New Hampshire (G.J.); Biopharm Consulting Partners, Ambler, Pennsylvania (J.H.L.); and Genetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, Massachusetts (C.Z., J.B.K., C.M.E., W.X., L.Q., D.Y.K., R.E.T.).
Robert A RissmanDepartment of Neurosciences, University of California, San Diego, La Jolla, California (S.L.W., K.D.R., P.D.N., A.B., U.V., D.M., L.M., W.C.M., R.A.R.); Integrated Nonclinical Development Solutions, Ann Arbor, Michigan (S.K.D.); NuPharmAdvise, Sanbornton, New Hampshire (G.J.); Biopharm Consulting Partners, Ambler, Pennsylvania (J.H.L.); and Genetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, Massachusetts (C.Z., J.B.K., C.M.E., W.X., L.Q., D.Y.K., R.E.T.).
Rudolph E TanziDepartment of Neurosciences, University of California, San Diego, La Jolla, California (S.L.W., K.D.R., P.D.N., A.B., U.V., D.M., L.M., W.C.M., R.A.R.); Integrated Nonclinical Development Solutions, Ann Arbor, Michigan (S.K.D.); NuPharmAdvise, Sanbornton, New Hampshire (G.J.); Biopharm Consulting Partners, Ambler, Pennsylvania (J.H.L.); and Genetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, Massachusetts (C.Z., J.B.K., C.M.E., W.X., L.Q., D.Y.K., R.E.T.).
University of California, San Diego · USMassachusetts General Hospital · US

Funding

TRANSGENICS AND PRESENILIN FUNCTIONP01AG015379 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI TANZI, RUDOLPH EMILE · 1998 to 2023
$51.3M
Role of the g-secretase/PS1 complex in APP processingR01AG014713 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI KIM, DOO YEON · 1997 to 2018
$5.9M
A novel human 3D neural cell culture system for the characterization of AD genesRF1AG048080 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI KIM, DOO YEON, TANZI, RUDOLPH EMILE · 2014 to 2014
$2.1M
Optimization of Soluble Gamma-secretase Modulators for the Treatment of AlzheimerU01NS074501 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI WAGNER, STEVEN LEE · 2011 to 2015
$1.4M
NIA NIH HHS P01 AG015379NIA NIH HHS R01 AG014713NIA NIH HHS RF1 AG048080NINDS NIH HHS U01 NS074501
6 · The paper itself

Abstract

Alzheimer's disease (AD) is characterized neuropathologically by an abundance of 1) neuritic plaques, which are primarily composed of a fibrillar 42-amino-acid amyloid-

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAmyloid beta-Protein PrecursorAmyloid Precursor Protein SecretasesAnimalsCells, CulturedCentral Nervous SystemDose-Response Relationship, DrugEnzyme InhibitorsHumansMacaca fascicularisMaleMiceMice, Inbred C57BLMice, TransgenicPeptide FragmentsAmyloid beta-Peptidesamyloid beta-protein (1-42)Amyloid beta-Protein PrecursorAmyloid Precursor Protein SecretasesBPN-15606Enzyme InhibitorsPeptide FragmentsPhenethylaminesPyridazinestau Proteins

Identifiers

PMID28416568
PMCPMC5454592
OpenAlexW2606115324

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.